Q3 2012 · —
Revenue$175.52M$175.52M +139.5% vs Q3 2011+41.3% vs Q2 2012
Net Income$33.21M$33.21M +2.2% vs Q3 2011+22.3% vs Q2 2012
EPS Diluted$0.55$0.55 −20.3% vs Q3 2011+22.2% vs Q2 2012
Gross Profit$141,501,000+107.1%
Operating Income$55,300,000+64.1%
Operating Cash Flowderived$44,143,000−4.1%
Free Cash Flowderived$41,644,000−8.9%
Margins · derived
Gross margin80.6%−12.6 pt vs Q3 2011
Operating margin31.5%−14.5 pt vs Q3 2011
Net margin18.9%−25.4 pt vs Q3 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|
| Revenue | $175.52M | $73.29M | $73.29M |
| Net Income | $33.21M | $32.48M | $32.48M |
| EPS Diluted | $0.55 | $0.69 | $0.69 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR